| Amcor Plc (AMC) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$8,984 |
Form 4s
|
29 Aug 2024 9:35AM |
$16.530 |
$13.040 |
fallen by
21.11%
|
|
| Cromwell Property Group (CMW) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,139 |
FY24 Results Presentation
|
29 Aug 2024 9:35AM |
$0.415 |
$0.435 |
risen by
4.82%
|
|
| Spacetalk Ltd (SPA) ORDINARY FULLY PAID |
Information Technology |
$10 |
Response to ASX Price Query
|
29 Aug 2024 9:35AM |
$0.037 |
$0.130 |
risen by
251.35%
|
|
SPA - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant price change of SPA securities from $0.026 to $0.037.
- SPA is not aware of any unannounced information explaining recent trading.
- SPA confirms compliance with Listing Rule 3.1.
- SPA's responses have been authorized under its continuous disclosure policy.
- ASX requested information regarding unexplained trading volumes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$308 |
FY24 Results Investor Presentation
|
29 Aug 2024 9:34AM |
$0.205 |
$0.300 |
risen by
46.34%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- Transformational merger of BlueBet and betr completed.
- Strategic exit from the US to focus on the Australian market.
- Successful rebranding and customer migration to the betr brand.
- Realization of significant operating efficiencies and synergies.
- Record quarterly metrics show continued momentum in Australian trading.
- Group turnover up 18% compared to the previous corresponding period (pcp).
- Achieved the majority of technology-related synergies ahead of budget.
- Positive Australian trading momentum with first EBITDA positive year.
- Improved financial performance with a strong focus on customer retention and engagement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Prospect Resources Limited (PSC) ORDINARY FULLY PAID |
Materials |
$140 |
Share Purchase Plan Closing 4 September 2024
|
29 Aug 2024 9:34AM |
$0.100 |
$0.200 |
risen by
100%
|
|
| Resimac Group Limited (RMC) ORDINARY FULLY PAID |
Financials |
$384 |
Resimac announces FY24 normalised NPAT of $43.1 million
|
29 Aug 2024 9:34AM |
$0.915 |
$0.970 |
risen by
6.01%
|
|
RMC - Price-sensitive ASX Announcement
Full Release
Key Points
- Normalised NPAT of $43.1 million down 42% on FY23
- Statutory NPAT of $34.8 million down 47% on FY23
- Originations of $5.1 billion, up 21% on FY23
- AUM increased 2% to $14.0 billion
- Home loans decreased $0.2 billion to $12.9 billion
- Asset Finance increased $0.5 billion to $1.1 billion, up 76% on FY23
- NIM decreased 12 bps to 1.56% for FY24
- Opex down 3.3% or $2.8m versus FY23
- Fully franked dividend of 3.5 cents per share for 2H24, 7.0 cents for the full year
- Continued progress on diversification into asset finance
- Stability in Home Loans portfolio and significant growth in Asset Finance
- Increased broker applications and home loan settlements
- Recovery in Assets Under Management in the latter half of FY24
- Improved pricing on Residential Mortgage-Backed Securities deals
- Strong balance sheet and stable funding platform going into FY25
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$308 |
BlueBet FY24 results
|
29 Aug 2024 9:34AM |
$0.205 |
$0.300 |
risen by
46.34%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- Transformational merger with betr completed on 1 July 2024
- Record turnover and net win in core Australian business for FY24
- Improved financial performance with first positive normalised EBITDA since IPO
- Exit from the US market to focus on Australian operations
- Expectation to reach monthly EBITDA profitability in H1 FY25
- Synergies from the merger with betr to drive profitability
- Rebrand and customer migration completed in 59 days
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Carnaby Resources Limited (CNB) ORDINARY FULLY PAID |
Materials |
$72 |
Drilling Update - Mohawk Discovery Drill Holes
|
29 Aug 2024 9:34AM |
$0.390 |
$0.315 |
fallen by
19.23%
|
|
CNB - Price-sensitive ASX Announcement
Full Release
Key Points
- Carnaby Resources Limited (ASX: CNB) announced the first drilling results from the Mohawk Prospect, part of the Greater Duchess Copper Gold Project.
- The initial two drill holes at Mohawk intersected significant copper sulphide mineralisation over wide intervals.
- pXRF readings from the drill holes MKRC001 and MKRC008 recorded notable copper intervals, including 21m @ 1.3% Cu from 43m in MKRC001 and 26m @ 0.8% Cu from 96m in MKRC008.
- Costean assay results also showed a strong gold association with copper mineralisation, including 10m @ 1.6% Cu, 0.4g/t Au.
- A major undrilled FLTEM modelled conductor plate is likely associated with copper sulphide mineralisation and is set for upcoming drilling.
- The Mohawk discovery has significant regional implications, with further exploration planned along the >2km long Mohawk corridor.
- Additional drilling at the Lady Fanny and Wimberu prospects yielded noteworthy copper and gold intersections.
- A large airborne VTEM survey is scheduled to commence in mid-September targeting the Mohawk corridor and additional areas.
- Carnaby Resources is advancing pre-feasibility studies and investigating future development options for the Greater Duchess Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Resimac Group Limited (RMC) ORDINARY FULLY PAID |
Financials |
$384 |
Appendix 4E
|
29 Aug 2024 9:34AM |
$0.915 |
$0.970 |
risen by
6.01%
|
|
RMC - Price-sensitive ASX Announcement
Full Release
Key Points
- FY24 revenue from ordinary activities increased by 11% to $1,006,677,000.
- Profit from ordinary activities after tax attributable to members decreased by 48% to $34,590,000.
- Net comprehensive income for the year attributable to members decreased by 57% to $31,466,000.
- Final FY24 dividend declared is 3.50 cents per share, fully franked.
- Interim FY24 dividend paid was 3.50 cents per share, fully franked.
- Net tangible assets per share increased to $1.15 from $0.93 in FY23.
- Earnings per share for FY24 were 8.65 cents basic and 8.64 cents diluted, compared to 16.52 cents basic and 16.48 cents diluted in FY23.
- The company's net assets stood at $416,361,000 as of 30 June 2024.
- The Group revised its accounting treatment of trail commission payable to mortgage brokers.
- The Board declared a fully-franked final dividend of 3.5 cents per share, with a record date of 6 September 2024, payable on 20 September 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Way 2 Vat Ltd (W2V) ORDINARY FULLY PAID |
Information Technology |
$14 |
Application for quotation of securities - W2V
|
29 Aug 2024 9:33AM |
$0.012 |
$0.008 |
fallen by
33.33%
|
|
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$308 |
Appendix 4G and Corporate Governance Statement
|
29 Aug 2024 9:33AM |
$0.205 |
$0.300 |
risen by
46.34%
|
|
| Way 2 Vat Ltd (W2V) ORDINARY FULLY PAID |
Information Technology |
$14 |
Application for quotation of securities - W2V
|
29 Aug 2024 9:33AM |
$0.012 |
$0.008 |
fallen by
33.33%
|
|
| AVITA Medical, Inc. (AVH) CHESS DEPOSITARY INTERESTS 5:1 |
Health Care |
$129 |
Notification regarding unquoted securities - AVH
|
29 Aug 2024 9:33AM |
$2.660 |
$1.420 |
fallen by
46.62%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$687 |
Corporate Governance Statement
|
29 Aug 2024 9:33AM |
$13.900 |
$13.700 |
fallen by
1.44%
|
|
| Omni Bridgeway Limited (OBL) ORDINARY FULLY PAID US PROHIBITED |
Financials |
$454 |
FY24 Corporate Governance Statement and Appendix 4G
|
29 Aug 2024 9:33AM |
$0.840 |
$1.575 |
risen by
87.50%
|
|
| Perpetual Limited (PPT) ORDINARY FULLY PAID |
Financials |
$2,532 |
ASX Release - Correction Letter
|
29 Aug 2024 9:33AM |
$20.640 |
$22.080 |
risen by
6.98%
|
|
PPT - Price-sensitive ASX Announcement
Full Release
Key Points
- Perpetual Limited reported an underlying profit after tax (UPAT) for FY24 of A$206.1 million, up 26% on FY23.
- The total Assets Under Management (AUM) increased to A$215 billion.
- A final dividend of A$0.53 per share, 50% franked, was declared.
- Estimated cash proceeds for shareholders from the Scheme with KKR range between A$8.38 - A$9.82 per share.
- A simplification program aims to deliver annualised cost reductions of between A$25 million and A$35 million before tax, over two years.
- Orderly Board changes announced in anticipation of the completion of the transaction with KKR.
- Appointment of Bernard Reilly as CEO and Managing Director, succeeding Rob Adams.
- Perpetual's Wealth Management and Corporate Trust segments showed growth with respective UPBT increases of 15% and 4%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$308 |
Appendix 4E and FY24 Annual Report
|
29 Aug 2024 9:33AM |
$0.205 |
$0.300 |
risen by
46.34%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- BlueBet Holdings Ltd completed a transformational merger with betr, creating a leading Australian wagering operator.
- The company has exited the US market to focus on expanding its core Australian operations.
- Revenue increased by 19.8% to $59.5 million for the year ended 30 June 2024.
- The company reported a loss of $46.9 million, up 149.1% from the previous year.
- No dividends were paid or declared during the financial year.
- The merger with betr is expected to deliver $14 million in annualized cost savings.
- Active customers increased to 70,456, up 7.7% from the previous year.
- The company achieved its first full-year EBITDA positive result since IPO with an EBITDA of $3.3 million for its Australian operations.
- The company has implemented new compliance measures, including banning credit cards and integrating the National Self Exclusion Register.
- The strategic focus is now on growing market share in the Australian market and leveraging technology and product enhancements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$687 |
Appendix 4G
|
29 Aug 2024 9:32AM |
$13.900 |
$13.700 |
fallen by
1.44%
|
|
| Duxton Farms Ltd (DBF) ORDINARY FULLY PAID |
Consumer Staple |
$45 |
Update - Notification of buy-back - DBF
|
29 Aug 2024 9:32AM |
$1.595 |
$0.980 |
fallen by
38.56%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$687 |
Investor Presentation
|
29 Aug 2024 9:32AM |
$13.900 |
$13.700 |
fallen by
1.44%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- CLINUVEL Pharmaceuticals Limited is focused on melanocortin-based pharmaceuticals for skin and brain conditions.
- The clinical pipeline includes treatments for various conditions such as xeroderma pigmentosum (XP), infantile spasms (IS), multiple sclerosis (MS), and central nervous system (CNS) disorders.
- SCENESSE® (afamelanotide 16 mg) is used in the treatment of erythropoietic protoporphyria (EPP) and is being trialed for other conditions like variegate porphyria, adolescent and adult XP, and vitiligo.
- NEURACTHEL® is being developed for instant and modified release forms to treat IS, MS, and CNS disorders.
- The company aims to build a diversified pharmaceutical group with multiple products and conditions treated, focusing on research and development, in-house manufacturing, and disciplined capital deployment.
- Financial performance includes maintaining cash reserves and disciplined capital investments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$15 |
2024 Appendix 4E and Annual Report
|
29 Aug 2024 9:32AM |
$0.021 |
$0.018 |
fallen by
14.29%
|
|
AT1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 61% to AUD 4,086,535
- Loss from ordinary activities after tax decreased by 31% to AUD 6,847,803
- Basic and diluted earnings per share were both (1.079) cents
- No dividends were paid, recommended, or declared
- Net tangible assets per ordinary security decreased from 2.02 AUD cents to 1.25 AUD cents
- Financial statements audited with an unmodified opinion
- Annual General Meeting scheduled for on or about 15 November 2024
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Accent Group Limited (AX1) ORDINARY FULLY PAID |
Consumer Discretionary |
$875 |
Director Resignation
|
29 Aug 2024 9:32AM |
$2.030 |
$1.455 |
fallen by
28.33%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$687 |
CLINUVEL delivers increases in annual revenue, profit
|
29 Aug 2024 9:32AM |
$13.900 |
$13.700 |
fallen by
1.44%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- Annual profit after income tax of $35.6 million for FY2024, a 16% increase from the previous year
- Total revenues for FY2024 reached $95.3 million, a 15% increase driven by demand for SCENESSE®
- Net profit before income tax was $50.7 million, an 11% increase
- Cash reserves increased by 17% to $183.9 million
- Seventh consecutive annual franked dividend of $0.05 per share
- CLINUVEL has achieved eight consecutive years of profitability
- The company has expended 72% of its five-year $175 million expenses plan on R&D and corporate capacity expansion
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Omni Bridgeway Limited (OBL) ORDINARY FULLY PAID US PROHIBITED |
Financials |
$454 |
FY24 Full Year Results Investor Presentation
|
29 Aug 2024 9:31AM |
$0.840 |
$1.575 |
risen by
87.50%
|
|
OBL - Price-sensitive ASX Announcement
Full Release
Key Points
- Investment income and fee revenue decreased by 10% to A$277.0m.
- Portfolio fair value increased by 11% to A$2.8bn.
- Net profit after tax before non-controlling interests increased by A$29.6m to A$30.5m.
- OBL achieved a 2.7x multiple on invested capital (MOIC) and 53% internal rate of return (IRR) for FY24.
- Fair value conversion for 34 completions reached 118% in 2H24.
- OBL successfully launched Fund 8 in 1Q24 and raised significant fund capital across 3 funds.
- Cash operating expenses (opex) were A$89.7m, below the target of A$95m.
- OBL aims for A$700 million in new commitments and A$85 million in cash opex for FY25.
- The company plans a second close for Funds 4/5 series II and launching a new fund in FY25.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Iltani Resources Limited (ILT) ORDINARY FULLY PAID |
Materials |
$14 |
ILT readies for Herberton silver-indium & antimony drilling
|
29 Aug 2024 9:31AM |
$0.255 |
$0.210 |
fallen by
17.65%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
